This paper might be of interest to the BIT investors [1] as it is an independent (if biased) assessment of BIT225. Two things were very interesting.
1. BIT225 is thought to be too toxic to use. Quoting from the paper
Two acylguanidine-containing compounds, HMA (Fig. 1A) and BIT-225 (Fig. 1B), are reported to inhibit HIV-1 replication; however, both display substantial in vitro toxicity, particularly to T cells (5, 6, 34, 35). We therefore sought to design an acylguanidine-based derivative with a reduced cytotoxic component. We observed that the heterocyclic amino-pyrazine core of HMA resembles the heterocyclic core of methotrexate, which is also cytotoxic (46), and speculated that the high nitrogen density in these cores might be a cause.
2. HIV-1 resistance mutations to acylguanidines can be easily be isolated. The highly conserved structure of VPU does not seem to prevent HIV-1 resistance mutations arising in this protein.
1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5044834/
- Forums
- ASX - By Stock
- BIT Science Discussion
This paper might be of interest to the BIT investors [1] as it...
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIT (ASX) to my watchlist
|
|||||
Last
2.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $25.26M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 312047 | 2.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.7¢ | 42000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 312047 | 0.026 |
6 | 1398646 | 0.025 |
4 | 396000 | 0.024 |
2 | 430000 | 0.023 |
5 | 4245555 | 0.022 |
Price($) | Vol. | No. |
---|---|---|
0.027 | 42000 | 1 |
0.028 | 198191 | 3 |
0.029 | 555600 | 4 |
0.030 | 90000 | 3 |
0.031 | 109129 | 2 |
Last trade - 11.07am 30/08/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |
Day chart unavailable
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
SPONSORED BY The Market Online